Business
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on
About this update from Mustang Bio, Inc.
[{"type":"text","content":"WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”), have been selected for a poster presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (“ASTCT”) and Center for International Blood & Marrow Transplant Research (“CIBMTR”), taking place February 2 – 6, 2022 in Salt Lake City, Utah (“2022 Tandem Meetings”). MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Research Center (“Fred Hutch”). Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “The compelling clinical activity and favorable safety profile that MB-106 continues to demonstrate in the ongoing Phase 1/2 trial at Fred Hutch highlight its potential as an outpatient therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. We look forward to the updated data that will be presented by Fred Hutch at the 2022 Tandem Meetings, in particular for patients with diffuse large B cell lymphoma and Waldenstrom’s macroglobulinemia. We also look forward to advancing our MB-106 CD20-targeted CAR T cell therapy program towards a multicenter trial under Mustang’s IND in the current quarter.” Details of the presentation are as follows: Title: High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLLPoster Number: 225Dates and Times: Thursday, February 3, 6:45 pm to 8:15 pm and Saturday, February 5, 6:15 pm to 7:45 pmPresenter: Mazyar Shadman, M.D., M.P.H., Associate Professor, Clinical Research Division, Fred Hutch, Seattle, WA; Physician at Seattle Cancer Care Alliance; Associate Professor, Division of Medical Oncology, University of Washington School of Medicine For more information, please visit the 2022 Tandem Meetings website at https...